Abstract
Approximately one-third of patients with hepatitis C virus (HCV) genotype (GT) 1 infection live in East Asia. This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha-2a and ribavirin (PR) in HCV GT1-infected, treatment-naïve, Asian patients with compensated liver disease. This phase III, randomized study (NCT01725529) was conducted in China and South Korea. Patients received simeprevir 150 mg once daily (QD), simeprevir 100 mg QD, or placebo, in combination with PR for 12 weeks. Patients in the simeprevir groups received PR alone for a further 12 or 36 weeks based on response-guided treatment criteria. Patients in the placebo group received a further 36 weeks of PR alone. The primary efficacy endpoint was sustained virologic response 12 weeks after planned end of treatment (SVR12). Secondary endpoints were safety, pharmacokinetics, tolerability, and patient-reported outcomes. Overall, 457 patients were treated; the majority had GT1b infection (452/457 [99%]) and IL28B CC GT (364/457 [80%]). Of the 454 patients who had liver biopsy, 26 had cirrhosis (6%). SVR12 rates were superior for both the simeprevir 100 mg (89%; P = 0.003) and 150 mg (91%; P < 0.001) groups versus...Continue Reading
References
Nov 5, 1990·Health Policy·UNKNOWN EuroQol Group
Oct 5, 1993·PharmacoEconomics·M C ReillyE M Dukes
Aug 9, 2012·Health and Quality of Life Outcomes·Leah KleinmanDennis Revicki
Nov 13, 2012·Annual Review of Pharmacology and Toxicology·Jennifer J Kiser, Charles Flexner
Feb 2, 2013·Clinical Therapeutics·Mugdha SitoleMichael Malloy
Feb 28, 2013·Clinical Pharmacology and Therapeutics·Y TomitaY Sugiyama
Jul 3, 2013·Clinical Pharmacokinetics·Zoe E BarterKaren Rowland-Yeo
Jul 4, 2013·Methods in Molecular Biology·Diana KoletzkiLieven J Stuyver
Jul 24, 2013·Journal of Gastroenterology and Hepatology·Yan Cui, Jidong Jia
Oct 5, 2013·Journal of Gastroenterology and Hepatology·Huiying RaoHui Zhuang
Mar 8, 2014·Gastroenterology·Xavier FornsMaria Beumont-Mauviel
Mar 26, 2014·Gastroenterology·Lai Wei, Anna S F Lok
Jun 8, 2014·Lancet·Michael MannsMaria Beumont-Mauviel
Jun 8, 2014·Lancet·Ira M JacobsonMaria Beumont-Mauviel
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Aug 29, 2014·BMC Infectious Diseases·Jane ScottLeen Gilles
Dec 3, 2014·Journal of Hepatology·Oliver LenzSandra De Meyer
Dec 10, 2014·Journal of Viral Hepatitis·J ScottM Beumont
Dec 20, 2014·Journal of Viral Hepatitis·A A ButtUNKNOWN ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team
Jan 23, 2015·Journal of Gastroenterology and Hepatology·Miyako MurakawaMamoru Watanabe
Jun 23, 2015·Journal of Gastroenterology and Hepatology·Eiichi OgawaJun Hayashi
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Thierry VerbinnenOliver Lenz
Citations
May 14, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S RenX Chen
Oct 21, 2016·European Journal of Clinical Pharmacology·Helena H BorbaRoberto Pontarolo
Feb 28, 2017·Antiviral Research·Guangdi Li, Erik De Clercq
Oct 4, 2017·Antimicrobial Agents and Chemotherapy·Stefan BourgeoisSivi Ouwerkerk-Mahadevan
Nov 30, 2016·Clinical Pharmacokinetics·Jan SnoeysSivi Ouwerkerk-Mahadevan
Oct 15, 2019·Journal of Clinical and Translational Hepatology·Lai WeiJinzi J Wu
Aug 22, 2018·Immunological Reviews·Rubesh RajaNarendra M Dixit